Imagen de Portada

European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet‐INNOCHRON COST Action based on a systematic evidence review

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Francesca Fioredda, Michail Spanoudakis, Julia Skokowa, Hannah Tamary, Piero Farruggia, Antonio Almeida, Daniela Guardo, Jan Palmblad, Petter Höglund, Ivo P. Touw, Cornelia Zeidler, Alan J. Warren, Mario Csenar, Nicole Skoetz, Elio Castagnola, Erica Ricci, David C. Dale, Peter E. Newburger, Karl Welte, Helen A. Papadaki, Carlo Dufour
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	HemaSphere
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies
por: John G. Gribben, et al.
Publicado: (2025)

Antibiotic‐associated neutropenia is marked by the depletion of intestinal Lachnospiraceae and associated metabolites in pediatric patients
por: Josaura Fernandez‐Sanchez, et al.
Publicado: (2024)

Expanding the phenotypic and genetic landscape of congenital neutropenia through whole‐exome and genome sequencing
por: Séverine Marti, et al.
Publicado: (2025)

ATMPs prepared under hospital exemption: European Blood Alliance position paper
por: Dragoslav Domanović, et al.
Publicado: (2025)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Publicado: (2025)

Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
por: Niels W. C. J. van de Donk, et al.
Publicado: (2025)

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
por: Thomas Chatzikonstantinou, et al.
Publicado: (2024)

Hematology in times of crisis: Lessons learned and strategic priorities from the EHA–ASH Joint Workshop on Ukraine
por: Oleksandr Istomin, et al.
Publicado: (2026)

European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
por: Niccolò Bolli, et al.
Publicado: (2025)

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL
por: Sarka Pavlova, et al.
Publicado: (2025)

Issue Information
Publicado: (2025)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
por: Raúl Córdoba, et al.
Publicado: (2026)

Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
por: Anna Ossami Saidy, et al.
Publicado: (2025)

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
por: Enrico Attardi, et al.
Publicado: (2024)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
por: Henri C. Hupe, et al.
Publicado: (2025)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
por: Jan‐Niklas Eckardt, et al.
Publicado: (2025)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
por: Konstanze Döhner, et al.
Publicado: (2025)

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
por: David A. Sallman, et al.
Publicado: (2025)

TET3 regulates hematopoietic stem cell homeostasis during embryonic and adult hematopoiesis
por: Harmony C. Ketchum, et al.
Publicado: (2025)

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second‐line therapy in pediatric chronic myeloid leukemia
por: Stephanie Sembill, et al.
Publicado: (2026)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
por: Uwe Platzbecker, et al.
Publicado: (2025)

HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond
por: Sotiroula Chatzimatthaiou, et al.
Publicado: (2025)

MMS22L is a novel key actor of normal and pathological erythropoiesis
por: Elia Colin, et al.
Publicado: (2025)

Correction to “Quality of vitamin K antagonist treatment during the last year of life”
Publicado: (2025)

Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
por: Daniel Mazza Matos
Publicado: (2026)

Publication Only
Publicado: (2025)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
por: Cristina A. Tentori, et al.
Publicado: (2024)

Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
por: Rebeqa Gunnarsson, et al.
Publicado: (2025)

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
por: Mwanasha H. Merrill, et al.
Publicado: (2025)

Patterns of immune recovery after axicabtagene ciloleucel for aggressive B‐cell lymphoma
por: André Airosa Pardal, et al.
Publicado: (2025)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
por: Martijn W. C. Verbeek, et al.
Publicado: (2025)

Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation
por: Suzana da Silva‐Benedito, et al.
Publicado: (2026)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
por: Thomas C. Wiemers, et al.
Publicado: (2026)

Dynamic evolution of TCF3‐PBX1 leukemias at the single‐cell level under chemotherapy pressure
por: Mira Kusterer, et al.
Publicado: (2025)

Issue Information
Publicado: (2024)

APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications
por: Francesco Mannelli, et al.
Publicado: (2026)

Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation
por: Konradin F. Müskens, et al.
Publicado: (2024)

Can health inequalities in sickle cell disease be addressed through novel therapies?
por: Stephen P. Hibbs, et al.
Publicado: (2025)

Issue Information
Publicado: (2024)

Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients
por: Shoshana Burke, et al.
Publicado: (2025)